- Price
- $31.49
- Day
- 0.00%
- Mkt Cap
- $3.85B
- 52W Range
- $19.05 – $32.56
- Volume
- 0
- Beta
- 0.74
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
The Italian pharma company grows its presence in the U.S. market and strengthens its global leadership in Brain Health and Rare Diseases Completion of the transaction gives Angelini Pharma ownership of Catalyst's product portfolio The transaction is being carried out with the participation of funds managed by Blackstone CDP Equity approves €1 billion investment in Angelini Pharma Italy remains a strategic production and scientific hub ROME and CORAL GABLES, Fla., July 16, 2026 (GLOBE NEWSWIRE) -- Angelini Pharma S.p.A.
Read full article
Angelini Pharma said on Thursday it had completed the acquisition of U.S. rare-disease drug maker Catalyst Pharmaceuticals in a $4.1 billion deal involving Italian state lender CDP.
Read full article